UiPath Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
Fourth Quarter Highlights Revenue of $424 million increases 5 percent year-over-year ARR of $1.666 billion increases 14 percent year-over-year GAAP operating income... Read more.
SentinelOne Announces Fourth Quarter and Fiscal Year 2025 Financial Results
Revenue increased 29% year-over-year ARR up 27% year-over-year MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–SentinelOne, Inc. (NYSE: S) today announced financial... Read more.
ย TopBloc Named 2025 Workday Business Impact Partner of the Year
ย TopBloc team honored for transformative customer outcomes and record-breaking number of Workday implementations CHICAGO–(BUSINESS WIRE)–$asgn–TopBloc,... Read more.
Two Navajo Nation Robotics Teams Qualify for International Competition at Rezbotics, Sponsored by Navajo Transitional Energy Company
FARMINGTON, N.M.–(BUSINESS WIRE)–Two Navajo Nation-based robotics teams are headed to an international robotics competition after winning Rezbotics,... Read more.
Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
DOR/ISL demonstrated non-inferiority and a similar safety profile to comparator antiretroviral therapies in adults with virologically suppressed HIV-1 RAHWAY, N.J.–(BUSINESS... Read more.
Aviator LLC Grants Exclusive IP License to Aviator Studio, Wins Trademark Case in Georgia
TBILISI, Georgia–(BUSINESS WIRE)–Aviator LLC has granted Aviator Studio (https://aviator.studio) an exclusive, irrevocable global license for its branding... Read more.
MRVI INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO–(BUSINESS WIRE)–The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Maravai LifeSciences Holdings,... Read more.
TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes
No drug associated adverse effects were reported Oral drug was well tolerated, and no clinically significant findings or safety concerns were noted Escalation to... Read more.
CORRECTING and REPLACING VIDEO Inflection Global Education Well-Being Platform Expands Support for Employees Navigating Relationship Challenges
SAN FRANCISCO & AUCKLAND, New Zealand–(BUSINESS WIRE)–Please replace the video accompanying the release dated March 6, 2025, with the accompanying... Read more.
SMTC CLASS ACTION NOTICE: Kirby McInerney LLP Files Securities Class Action on Behalf of Semtech Corporation Investors
NEW YORK–(BUSINESS WIRE)–$SMTC #CLASSACTIONLAWSUIT–The law firm of Kirby McInerney LLP announces that it has filed a class action lawsuit in the... Read more.